Market news

Motley Fool Press Release.

Heron Therapeutics Inc (HRTX) has an average rating of Buy and mean price target of $6.25, according

Heron Therapeutics: Q2 Earnings Snapshot

CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in deta

Heron Therapeutics is back in focus after analysts trimmed their fair value price target from US$3.00 to US$2.00 per share, a reset that puts the current debate around the company’s outlook front and center. Much of this shift tracks recent Street commentary following the Cinvanti patent decision, with analysts reassessing downside risk from potential generic competition against any upside from an appeal and execution on the existing portfolio. As you read on, you will see how these changing...